Most colorectal cancers grow from small, benign growths called polyps that accumulate genetic damage over roughly five to ten years before turning malignant. This stepwise transformation, known as the adenoma-carcinoma sequence, was first mapped in detail in the late 1980s and remains the central framework for understanding how colon cancer develops. The process is not a single switch that flips but a series of molecular missteps, each pushing normal tissue a little closer to cancer, and understanding those steps explains why screening colonoscopies are so effective at preventing deaths.
The Foundational Model
The idea that colon cancer emerges through an orderly accumulation of genetic hits was established by a landmark study showing that the development of colorectal tumors typically involves the activation of an oncogene combined with the loss of several genes that normally suppress tumor growth.1PubMed. Genetic alterations during colorectal-tumor development Before this model gained traction, cancer was widely treated as an unpredictable event. The adenoma-carcinoma sequence replaced that view with something more structured: a polyp forms, acquires additional mutations, grows larger and more abnormal, and eventually gains the ability to invade surrounding tissue. Not every polyp completes this journey. In fact, most never do. But virtually all conventional colorectal cancers pass through these stages, which is why catching and removing polyps early interrupts the process so reliably.
Where It Starts With the APC Gene
The opening act in most cases is a mutation in a gene called APC. This gene normally acts as a brake on cell growth in the colon lining. When APC is knocked out, cells start dividing more than they should, forming a small cluster that becomes a polyp. Activation of the growth-signaling pathway controlled by APC is considered a critical early event in colon cancer development.2PubMed Central. Wnt signaling and colon carcinogenesis: beyond APC People born with one defective copy of APC, as in the inherited condition familial adenomatous polyposis, develop hundreds or thousands of polyps starting in their teens, which is powerful evidence that this gene’s loss is enough to get polyps started.
At this stage the polyp is benign. It looks like a small bump on the colon wall, usually just a few millimeters across, and it consists of cells that are growing faster than normal but still roughly organized. It can sit there for years without doing anything dangerous. The trouble begins when additional mutations pile on.
The Middle Stage and KRAS
As a polyp grows, it has more opportunities to acquire new mutations simply because its cells are dividing more often. One of the most important intermediate mutations involves the KRAS gene, which acts as a growth accelerator. A study examining colonic polyps found that KRAS mutations appeared far more often in advanced adenomas than in early ones, and that polyps carrying KRAS mutations were more likely to be larger and to show more severe cellular abnormality.3PubMed Central. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia The numbers are telling: KRAS mutations were found in about 22% of advanced adenomas compared with under 5% of non-advanced ones, and nearly half of polyps with high-grade dysplasia carried the mutation.
This middle phase is where the polyp transitions from something your gastroenterologist might call “nothing to worry about” to something flagged as an advanced adenoma. Advanced adenomas are defined by their size (typically a centimeter or more), the presence of villous tissue architecture, or high-grade dysplasia, meaning the cells are starting to look genuinely abnormal under the microscope. Polyps a centimeter or larger on the left side of the colon are more likely to show these concerning features, and about 1% already harbor cancer at the time of removal.4Gastro Hep Advances. Clinical Morphology, Histopathology, and Anatomical Distribution of Sporadic Colorectal Polyps in Chinese Patients
The Final Push and TP53
The transition from advanced adenoma to actual cancer usually requires one more major genetic event: the loss or mutation of TP53, sometimes called the “guardian of the genome.” TP53 normally forces damaged cells to stop growing or self-destruct. When it is disabled, cells with dangerous mutations survive and keep multiplying. Research on laterally spreading tumors in the colon found that TP53 mutations were never detected in adenomas but appeared specifically in cancer samples, suggesting the mutation marks the actual crossing point from benign to malignant.5PubMed Central. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors
Animal studies reinforce the picture: loss of normal p53 in the intestine appears to contribute to the invasion of benign tumors into surrounding tissue, though other genetic changes in the background are usually needed for that process to fully take hold.6PubMed Central. Mutant p53 in colon cancer In practical terms, this means that a polyp with mutant APC and KRAS is growing fast and looks abnormal, but it still respects the boundary between the colon lining and deeper tissue. It takes a TP53 failure for the growth to break through that boundary and become an invasive cancer.
How Long the Whole Process Takes
The exact speed varies from person to person, but estimates suggest that a visible polyp typically takes five to ten years to become a carcinoma.7Gastroenterology Report. Colorectal polyps and polyposis syndromes That long window is the entire reason screening colonoscopies work. If you get a colonoscopy every ten years and any polyps found are removed, the odds that a new polyp will form and progress all the way to cancer between screenings are very low. The timeline is not fixed, though. People with certain hereditary syndromes can move through the sequence faster, and some polyps never progress at all regardless of how long they sit in the colon.
The Serrated Pathway
Not all colorectal cancers follow the classic APC-then-KRAS-then-TP53 playbook. Roughly 20 to 30% arise through what is called the serrated neoplasia pathway, which starts not from a typical adenomatous polyp but from flat, saw-toothed growths called sessile serrated lesions.8American Journal of Case Reports. Diagnostic Challenges in Sessile Serrated Lesions: Progression to Adenocarcinoma in a High-Risk Patient These lesions tend to sit in the right side of the colon, are often flat and pale, and are notoriously easy to miss during colonoscopy because they blend in with normal tissue.
Instead of APC, the serrated pathway is typically driven by a mutation in the BRAF gene. BRAF mutations are considered a specific molecular driver of this route, and proximal (right-sided) serrated polyps carrying the mutation carry a high risk of progressing to cancer.9PubMed Central. BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential The serrated pathway also relies heavily on an epigenetic mechanism rather than straightforward gene mutations: widespread methylation of gene promoters silences tumor suppressor genes without actually changing their DNA code. This methylation-heavy profile is called CIMP, and it is a hallmark of cancers arising through this route.10PubMed Central. The CpG island methylator phenotype (CIMP) in colorectal cancer
Understanding the serrated pathway matters for screening. Because serrated lesions look different from classic polyps and sit in a harder-to-examine part of the colon, early colonoscopy guidelines were not optimized to catch them. Improved bowel preparation, better endoscopic technique, and awareness of what these flat lesions look like have all helped, but serrated lesions remain a recognized weak spot in standard screening.
Gene Silencing Through Methylation
Methylation is the body’s normal system for switching genes on and off during development, but in colorectal tumors it gets hijacked. Specific regions of DNA called CpG islands, which sit near gene promoters, become abnormally methylated, effectively shutting down genes the cell needs to keep growth in check. One early study of this phenomenon found that tumors with heavy methylation also tended to show silencing of a gene involved in DNA repair (hMLH1), linking methylation to yet another form of genomic instability.11PubMed. CpG island methylator phenotype in colorectal cancer Research on patients with multiple hyperplastic polyps showed that over 40% of their polyps displayed high-level methylation at multiple sites, supporting the idea that some people’s colons are prone to this kind of epigenetic silencing.12PubMed Central. Concordant CpG island methylation in hyperplastic polyposis
The practical takeaway is that colorectal cancer does not always need a mutated gene to lose a tumor suppressor. Sometimes the gene is perfectly intact but chemically gagged. This distinction has implications for treatment, since methylation-driven cancers can behave differently from mutation-driven ones in terms of prognosis and response to therapy.
Lynch Syndrome and DNA Repair Failures
Lynch syndrome, the most common hereditary predisposition to colorectal cancer, bypasses parts of the classic sequence by disabling the cell’s DNA proofreading machinery. People with Lynch syndrome inherit a defective copy of a mismatch repair gene, which means their cells accumulate mutations at an accelerated rate. The hallmark of this defect is microsatellite instability, which is also seen in roughly 15 to 20% of non-inherited colon cancers.13PubMed. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome
In Lynch syndrome, even adenomatous polyps show signs of repair failure. One study found that about 40% of adenomatous polyps from Lynch syndrome patients already showed high-level microsatellite instability, and all adenomas a centimeter or larger had both instability and loss of repair-protein expression.14Cancer Prevention Research. Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps The finding that repair deficiency increases with polyp size suggests that loss of DNA repair is not the first event but an accelerant that speeds a polyp’s progression. Lynch syndrome patients are therefore advised to undergo colonoscopy far more frequently than the general population, often every one to two years starting in early adulthood.
Why Location in the Colon Matters
The colon is not one uniform tube. Cancers arising on the right (proximal) side differ from those on the left (distal) side in their molecular profiles, how they look under the microscope, and how they respond to treatment. Right-sided cancers are more often driven by microsatellite instability and BRAF mutations, tend to follow the serrated pathway, and are more frequently mucinous in appearance.15PubMed. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features Left-sided cancers more often show chromosomal instability, the classic APC-KRAS-TP53 sequence, and amplification of growth-factor receptors that can be targeted with specific drugs.16PubMed. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles
These differences have real-world consequences. Right-sided tumors tend to be diagnosed at a later stage because they can grow large without causing obvious symptoms like bleeding, while left-sided tumors are more likely to cause changes in bowel habits or visible blood in the stool. Treatment decisions, including which targeted therapies are appropriate, also depend on tumor location. The distinction reinforces the point that “colorectal cancer” is really an umbrella term covering several biologically different diseases that happen to share an organ.
How Polypectomy Interrupts the Sequence
The strongest practical validation of the adenoma-carcinoma model comes from polypectomy studies. A landmark trial found that removing adenomatous polyps during colonoscopy reduced the incidence of colorectal cancer by 76 to 90% compared with expected rates in reference populations.17PubMed. Prevention of colorectal cancer by colonoscopic polypectomy Long-term follow-up of the same cohort showed that the benefit persisted: after a median of nearly 16 years, death from colorectal cancer was reduced by about 53% among patients who had adenomas removed.18PubMed Central. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths
These numbers are remarkable for a cancer-prevention strategy. They also explain why guidelines push so hard for screening colonoscopies: the procedure is not just finding cancer early but actively preventing it by removing the precursor before it can complete the sequence. Even stool-based screening tests work by flagging people who need a colonoscopy where polyps can then be removed.
What Makes Some Polyps Riskier Than Others
Not all polyps carry the same threat. Reviews of the evidence have found that villous features, high-grade dysplasia, larger size, and having three or more adenomas at the time of first colonoscopy are all associated with a higher risk of future advanced adenomas or colorectal cancer.19PubMed Central. Colon adenoma features and their impact on risk of future advanced adenomas and colorectal cancer This is why your colonoscopy report does not just say “polyp found.” It specifies the size, number, location, and microscopic appearance of each polyp, and your follow-up schedule is tailored based on those features. Someone with a single small tubular adenoma might be told to come back in seven to ten years. Someone with a large villous adenoma with high-grade dysplasia may be advised to return in one to three years.
Diet, the Gut Microbiome, and the Tumor Landscape
The genetic steps of the adenoma-carcinoma sequence do not happen in a vacuum. Diet appears to influence how readily polyps form and progress. Diets high in rapidly absorbed carbohydrates, sugary beverages, red and processed meat, and low in fiber have been linked to both polyp formation and colorectal cancer risk, likely through chronic metabolic changes that promote cell growth in the colon lining.20Frontiers in Nutrition. A review of dietary patterns and the colorectal polyp-to-carcinoma sequence: polyp occurrence, polyp recurrence, and colorectal cancer
The gut microbiome is another layer. Research comparing gut bacteria in people with colorectal polyps versus healthy individuals found that certain inflammation-promoting species were more abundant in polyp patients, while beneficial bacteria were reduced.21Scientific Reports. Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individuals The hypothesis is that an imbalanced microbiome creates a chronically inflamed environment in the colon that favors the survival and growth of cells already carrying early mutations. This area of research is still early, but it adds a layer beyond pure genetics to the story of how polyps become cancers.
Physical Changes in the Tissue Itself
There is also a mechanical dimension to the sequence that gets little public attention. As cells accumulate mutations and begin growing abnormally, the physical properties of the tissue change. Cancerous and pre-cancerous colon tissue becomes softer and more deformable than normal tissue. Research has suggested that these mechanical shifts are not just a side effect of cancer but may actively contribute to progression, helping abnormal cells break free from their normal positions and invade deeper layers.22PubMed Central. Changes in cellular mechanical properties during onset or progression of colorectal cancer This line of investigation is still developing, but it hints at future diagnostic approaches that could use tissue stiffness measurements to identify suspicious areas during endoscopy.
Emerging Screening Beyond the Scope
Colonoscopy remains the gold standard for both detection and prevention, but newer approaches are expanding options. Liquid biopsy techniques that analyze circulating tumor DNA, circulating tumor cells, or tumor-associated platelets in a simple blood draw are being developed for early colorectal cancer detection, staging, and monitoring for recurrence.23PubMed Central. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring Meanwhile, stool-based tests continue to improve. The fecal immunochemical test has been the backbone of non-invasive screening, and newer assays combining it with other stool markers are pushing sensitivity higher.24PubMed Central. Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring None of these replace polypectomy, since detecting a polyp through a blood or stool test still means you need a colonoscopy to remove it. But they lower the barrier to initial screening, especially for people who are reluctant to undergo a colonoscopy without a specific reason.
The adenoma-carcinoma sequence is one of the best-understood progressions in all of cancer biology, and that understanding has translated directly into lives saved. The molecular details continue to be refined with each year’s research, but the practical message has been clear for decades: polyps are the precursors, removing them prevents cancer, and screening catches them while they are still harmless.